How to eliminate gastric cancer-related death worldwide?
How to eliminate gastric cancer-related death worldwide?, Published online: 26 April 2018; doi:10.1038/s41571-018-0029-8Helicobacter pylori eradication therapy is effective in preventing gastric cancer, even in patients with advanced pre-neoplastic lesions (gastric atrophy and/or intestinal metaplasia). We must now focus on how to accomplish the goal of eliminating gastric cancer-related death worldwide; strategies for screening and treatment of gastric neoplasia (primary prevention) and post-treatment surveillance (secondary prevention) are discussed herein. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Yoshio Yamaoka Source Type: research

Does nonmetastatic castration-resistant prostate cancer still exist?
Does nonmetastatic castration-resistant prostate cancer still exist?, Published online: 23 April 2018; doi:10.1038/s41571-018-0025-zAfter almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 23, 2018 Category: Cancer & Oncology Authors: Celestia S. Higano Source Type: research

The multiple myelomas — current concepts in cytogenetic classification and therapy
The multiple myelomas — current concepts in cytogenetic classification and therapy, Published online: 23 April 2018; doi:10.1038/s41571-018-0018-yThe multiple myelomas (MMs) are heterogeneous malignancies that are nearly always associated with chromosomal abnormalities, which can be considered either primary or secondary abnormalities. The classification of MM according to the underlying primary cytogenetic abnormality might enable the development of better treatment strategies. The authors describe treatment approaches that consider the current standard of care for patients with MM along with recommendations for certain...
Source: Nature Clinical Practice Oncology - April 23, 2018 Category: Cancer & Oncology Authors: Shaji K. Kumar S. Vincent Rajkumar Source Type: research

The paradox of precision medicine
We describe how approaches to precision medicine can lead, paradoxically, to increased levels of uncertainty. We offer recommendations for how physicians can better navigate new uncertainties in precision medicine. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 19, 2018 Category: Cancer & Oncology Authors: Jonathan Kimmelman Ian Tannock Source Type: research

Nivolumab effective in treatment-resistant HL
Nivolumab effective in treatment-resistant HL, Published online: 18 April 2018; doi:10.1038/s41571-018-0022-2Nivolumab effective in treatment-resistant HL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

Crizotinib active in patients of East Asian ethnicity
Crizotinib active in patients of East Asian ethnicity, Published online: 18 April 2018; doi:10.1038/s41571-018-0024-0Crizotinib active in patients of East Asian ethnicity (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

Combination effective against brain metastases
Combination effective against brain metastases, Published online: 18 April 2018; doi:10.1038/s41571-018-0023-1Combination effective against brain metastases (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 18, 2018 Category: Cancer & Oncology Source Type: research

CheckMate 214 — a winning combination?
CheckMate 214 — a winning combination?, Published online: 17 April 2018; doi:10.1038/s41571-018-0020-4CheckMate 214 — a winning combination? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours
Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours, Published online: 17 April 2018; doi:10.1038/s41571-018-0012-4Patients with sarcomas have historically been treated with surgery and/or chemotherapy, although the outcomes achieved with these approaches, especially in advanced-stage disease, are often disappointing. In this Review, the authors describe the opportunities created by selective use of targeted therapies on the basis of the biological characteristics of individual tumours. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Armelle Dufresne Mehdi Brahmi Marie Karanian Jean-Yves Blay Source Type: research

Analysis of DNA methylation in cancer: location revisited
Analysis of DNA methylation in cancer: location revisited, Published online: 17 April 2018; doi:10.1038/s41571-018-0004-4Despite extensive research efforts, very few DNA methylation-based biomarkers have been implemented clinically. In this Perspective, the authors describe the importance of considering the genomic locations examined in determining the diagnostic or prognostic relevance of putative DNA methylation-based biomarkers. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 17, 2018 Category: Cancer & Oncology Authors: Alexander Koch Sophie C. Joosten Zheng Feng Tim C. de Ruijter Muriel X. Draht Veerle Melotte Kim M. Smits Jurgen Veeck James G. Herman Leander Van Neste Wim Van Criekinge Tim De Meyer Manon van Engeland Source Type: research

New subtypes of high-grade neuroendocrine tumours revealed
New subtypes of high-grade neuroendocrine tumours revealed, Published online: 16 April 2018; doi:10.1038/s41571-018-0015-1New subtypes of high-grade neuroendocrine tumours revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Targeted combination has synergy in MCL
Targeted combination has synergy in MCL, Published online: 16 April 2018; doi:10.1038/s41571-018-0021-3Targeted combination has synergy in MCL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease
Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease, Published online: 16 April 2018; doi:10.1038/s41571-018-0014-2Postoperative chemoradiotherapy versus radiotherapy for high-risk cutaneous disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Venetoclax–rituximab holds substantial promise in CLL
Venetoclax–rituximab holds substantial promise in CLL, Published online: 12 April 2018; doi:10.1038/s41571-018-0017-zVenetoclax–rituximab holds substantial promise in CLL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Encorafenib — a new agent for advanced-stage disease
Encorafenib — a new agent for advanced-stage disease, Published online: 12 April 2018; doi:10.1038/s41571-018-0019-xEncorafenib — a new agent for advanced-stage disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - April 12, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research